XML 53 R36.htm IDEA: XBRL DOCUMENT v3.21.1
SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 17, 2021
Oct. 01, 2020
Sep. 14, 2020
Mar. 18, 2020
Jul. 23, 2018
Oct. 19, 2017
Oct. 31, 2015
Mar. 31, 2021
Mar. 30, 2021
Dec. 31, 2020
Sep. 30, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Significant Accounting Policies [Line Items]                            
Common Stock, Par or Stated Value Per Share (in dollars per share)                   $ 0.001   $ 0.001 $ 0.001  
Gross proceeds                       $ 4,867,000    
Exercise price of warrants (in dollars per share)                   $ 2.36   $ 2.36    
Proceeds from private placement       $ 41,300,000                    
Notes Payable, Current                   $ 4,086,000   $ 4,086,000 $ 4,301,000  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount                       22,850,682 7,838,120 7,458,380
Rental expense                           $ 1,400,000
Operating Lease, Right-of-Use Asset                   5,567,000   $ 5,567,000 $ 5,677,000  
Operating Lease, Liability                   $ 5,887,000   $ 5,887,000 $ 5,700,000  
Incremental average borrowing rate at inception                       12.58%    
Subsequent Event [Member]                            
Significant Accounting Policies [Line Items]                            
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001                          
Shares Issued, Price Per Share 4.60                          
Share price $ 4.60                          
Gross proceeds $ 40,200,000               $ 8,800,000          
Number of shares issued (in shares) 8,749,999               1,867,552          
Seven Point Five Percentage Convertible Notes [Member]                            
Significant Accounting Policies [Line Items]                            
Interest rate (as a percent)                   7.50%   7.50%    
Notes Payable, Current                   $ 57,900,000   $ 57,900,000    
2018 Notes [Member]                            
Significant Accounting Policies [Line Items]                            
Notes Payable, Current                   $ 0   $ 0    
Term of debt                           5 years
Minimum [Member]                            
Significant Accounting Policies [Line Items]                            
Tax Rate Assumption Related To Deferred Tax Difference Reversal                   23.00%   23.00%    
Maximum [Member]                            
Significant Accounting Policies [Line Items]                            
Tax Rate Assumption Related To Deferred Tax Difference Reversal                   26.00%   26.00%    
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]                            
Significant Accounting Policies [Line Items]                            
Collaborative Arrangement Revenues Expenses Sharing Percentage             100.00%              
Chiesi US Agreement and Chiesi Ex US Agreement [Member]                            
Significant Accounting Policies [Line Items]                            
Upfront Nonrefundable Non-Creditable Payment Receivable           $ 25,000,000.0       $ 50,000,000.0   $ 50,000,000.0    
Chiesi US Agreement [Member]                            
Significant Accounting Policies [Line Items]                            
Upfront Nonrefundable Non-Creditable Payment Receivable         $ 25,000,000.0 25,000,000.0                
Additional Amounts Payable To Cover Development Costs         20,000,000.0                  
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones         $ 760,000,000.0         760,000,000.0   $ 760,000,000.0    
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract                     $ 6,200,000      
Chiesi US Agreement [Member] | Minimum [Member]                            
Significant Accounting Policies [Line Items]                            
Payment On Net Sales Percentage         15.00%             15.00%    
Chiesi US Agreement [Member] | Maximum [Member]                            
Significant Accounting Policies [Line Items]                            
Payment On Net Sales Percentage         40.00%             40.00%    
Chiesi Ex US Agreement [Member]                            
Significant Accounting Policies [Line Items]                            
Upfront Nonrefundable Non-Creditable Payment Receivable           25,000,000.0                
Additional Amounts Payable To Cover Development Costs           25,000,000.0                
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones           $ 320,000,000.0       320,000,000.0   $ 320,000,000.0    
Chiesi Ex US Agreement [Member] | Minimum [Member]                            
Significant Accounting Policies [Line Items]                            
Payment On Net Sales Percentage           15.00%           15.00%    
Chiesi Ex US Agreement [Member] | Maximum [Member]                            
Significant Accounting Policies [Line Items]                            
Payment On Net Sales Percentage           35.00%           35.00%    
ATM Shares                            
Significant Accounting Policies [Line Items]                            
Gross proceeds                   $ 5,000,000   $ 5,000,000.0    
Sale Of Stock Maximum Offering Price   $ 30,000,000                        
Number of shares issued (in shares)                   1,428,571   1,428,571    
ATM Shares | Subsequent Event [Member]                            
Significant Accounting Policies [Line Items]                            
Gross proceeds               $ 8,800,000            
Number of shares issued (in shares)               1,867,552            
Private Placement [Member]                            
Significant Accounting Policies [Line Items]                            
Share price       $ 2.485                    
Number of shares issued (in shares)     200,000 17,604,423                    
Purchase price (in dollars per share)       $ 2.485                    
Number of warrants issued (in shares)       17,604,423                    
Exercise price of warrants (in dollars per share)       $ 2.36                    
Exercise of warrants, commencement period       6 months                    
Term of warrants       5 years                    
Proceeds from private placement       $ 43,700,000